Screener
Monte Rosa Therapeutics, Inc. GLUE Q3 2026 earnings
Reported November 5, 2026 · Before market open
Revenue$54.4MBeat by $20.5M
EPS$0.03Beat by $0.24
Revenue estimate$33.9M
EPS estimate-$0.21
“The GFORCE-1 results reinforce our view that targeting NEK7 at the top of the NLRP3 signaling cascade could address a broader set of disease drivers than targeting individual downstream cytokines. Our planned Phase 2 studies in coronary artery disease (CAD), gout, and hidradenitis suppurativa, conditions with major unmet needs, are intended to deepen our understanding of the therapeutic potential of NEK7 degradation. In CAD, our innovative study design integrates molecular and imaging-based readouts to explore how MRT-8102's broad biological activity translates into changes in coronary plaque biology, to inform patient selection and design for an efficient future Phase 3 study.”
Next report
Date not yet announcedValuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Monte Rosa Therapeutics, Inc. report Q3 2026 earnings?
- Monte Rosa Therapeutics, Inc. (GLUE) reported Q3 2026 earnings on November 5, 2026 before market open.
- What were Monte Rosa Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Monte Rosa Therapeutics, Inc. reported revenue of $54.4M and eps of $0.03 for Q3 2026.
- Did Monte Rosa Therapeutics, Inc. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $33.9M by $20.5M. EPS beat the consensus estimate of $-0.21 by $0.24.
- How did Monte Rosa Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 325.9% from $12.8M a year earlier.
- Where can I find Monte Rosa Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-448527) and the 10-Q periodic report (0001193125-26-448568) directly on SEC EDGAR. The filing index links above go to sec.gov.
